Investor Presentaiton
Investor presentation
Full year 2018
In the USA, Victoza® CV indication and OzempicⓇ launch
contribute to the 27% GLP-1 market growth
USA GLP-1 TRX market development
Quarterly
TRX
(million)
Annual market growth (RHS)¹
Other GLP-1s
Dulaglutide
OzempicⓇ
Monthly
USA GLP-1 volume market share
NN GLP-1
VictozaⓇ
OzempicⓇ
2
1
Exenatide ER
TRX share
Market
VictozaⓇ growth
60% 1
35%
27%
30%
40%
25 %
20 %
20%
15%
10 %
0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2017 2017 2017 2017 2018 2018 2018 2018
Dec
2016
Slide 8
dulaglutide
exenatide
albiglutide
Source: IQVIA weekly NPA, week ending 4 Jan 2019 for Q4 2018; monthly NPA dated Nov 2018 TRX
Script Count for prior quarters
CV: Cardiovascular
1 Growth rate three months year over year
RHS: Right hand side
Source: IQVIA monthly NPA, Nov 2018; weekly NPA for Dec, week ending 4 Jan 2019
44.5%
43.0%
35.3%
12.3%
7.7%
Dec
2018View entire presentation